한글목차

세계의 마이크로바이옴 치료제 시장은 2025년 1억 9,711만 달러에서 2031년까지 10억 1,318만 달러로, CAGR 31.37%로 성장할 것으로 예측됩니다. 마이크로바이옴 치료제는 박테리아, 곰팡이, 바이러스로 구성된 미생물 군집인 인간의 마이크로바이옴을 조작하여 미생물의 균형을 회복시킴으로써 질병의 치료 및 예방을 목적으로 하는 생물제제의 일종입니다.

주요 시장 성장 촉진요인

바이오 치료 제품의 규제 승인 증가와 유리한 가이드라인이 주요 촉매제로 작용하여 시장을 실험적 연구에서 상업적 실현 가능성으로 전환하고 있습니다. 새로운 치료법의 성공적인 승인은 마이크로바이옴 회복의 기초 과학을 입증하고, 개발자의 신뢰와 임상 도입을 촉진하고 있습니다.

주요 시장 과제

복잡한 규제 환경은 세계 마이크로바이옴 치료제 시장의 성장을 저해하는 큰 장벽으로 작용하고 있습니다. 기존의 소분자 의약품과 달리, 마이크로바이옴 치료제는 살아있는 불균일한 생물학적 혼합물로 구성되어 있으며, 제조의 일관성, 안정성, 유효성 검증에 있으며, 특별한 어려움이 있습니다.

주요 시장 동향

특정 미생물 균주가 숙주의 면역 체계를 조절하고 체크포인트 억제제에 대한 내성을 극복할 수 있는 능력에 힘입어, 면역 종양학 보조제로서 마이크로바이옴 치료제의 통합이 중요한 동향으로 빠르게 주목받고 있습니다. 개발자들은 살아있는 생물제제가 종양 미세환경을 조성하여 PD-1/PD-L1 억제제와 같은 기존 암 면역치료제의 효능을 높이는 시너지 조합에 점점 더 집중하고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 유형별(FMT대 마이크로바이옴 의약품)
  • 용도별(클로스트리듐·디피실 감염증, 크론병, 염증성장질환, 당뇨병, 기타)
  • 지역별
  • 기업별(2025)
• 시장 맵

제6장 북미의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 마이크로바이옴 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 마이크로바이옴 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• 4D Pharma plc
• Enterome SA
• Finch Therapeutics Group, Inc.
• Vedanta Bioscience, Inc.
• Seres Therapeutics, Inc.
• Microbiotica Limited
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings Co., Ltd.
• AOBiome Therapeutics, Inc.
• Ferring Pharmaceuticals SA

제16장 전략적 제안

제17장 조사회사 소개·면책사항

영문목차

The Global Microbiome Therapeutics Market will grow from USD 197.11 Million in 2025 to USD 1013.18 Million by 2031 at a 31.37% CAGR. Microbiome therapeutics are a class of biological drugs designed to manipulate the human microbiome, comprising communities of bacteria, fungi, and viruses, to treat or prevent disease by restoring microbial balance.

Key Market Drivers

Increasing regulatory approvals and favorable guidelines for live biotherapeutic products act as a primary catalyst, transitioning the market from experimental research to commercial viability. The successful authorization of novel therapies validates the underlying science of microbiome restoration, encouraging developer confidence and clinical adoption. This shift is evident in the tangible revenue streams now generated by recently approved assets, which underscores the growing market uptake of these treatments.

Key Market Challenges

The complex regulatory landscape stands as a formidable barrier hampering the growth of the Global Microbiome Therapeutics Market. Unlike traditional small-molecule drugs, microbiome therapeutics consist of living, heterogeneous biological mixtures that present unique difficulties regarding manufacturing consistency, stability, and potency verification. The absence of standardized global guidelines for characterizing these live biotherapeutic products creates significant ambiguity for developers, who must navigate undefined pathways for clinical trial design and safety evaluation. This uncertainty directly stifles market expansion by inflating research costs and extending development timelines, making it difficult for companies to secure the necessary capital for late-stage commercialization.

Key Market Trends

The Integration of Microbiome Therapeutics as Immuno-Oncology Adjuvants is rapidly gaining traction as a pivotal trend, driven by the ability of specific microbial strains to modulate the host immune system and overcome resistance to checkpoint inhibitors. Developers are increasingly focusing on synergistic combinations where live biotherapeutic products prime the tumor microenvironment, thereby enhancing the efficacy of existing cancer immunotherapies like PD-1/PD-L1 blockers. This approach is moving beyond early-stage concepts into robust clinical validation, targeting difficult-to-treat solid tumors.

Key Market Players

• 4D Pharma plc
• Enterome SA
• Finch Therapeutics Group, Inc.
• Vedanta Bioscience, Inc.
• Seres Therapeutics, Inc.
• Microbiotica Limited
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings Co., Ltd.
• AOBiome Therapeutics, Inc.
• Ferring Pharmaceuticals SA

Report Scope:

In this report, the Global Microbiome Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Microbiome Therapeutics Market, By Type:

• FMT v/s Microbiome Drugs

Microbiome Therapeutics Market, By Application:

• C. Difficile
• Crohn's Disease
• Inflammatory Bowel Disease
• Diabetes
• Others

Microbiome Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Microbiome Therapeutics Market.

Available Customizations:

Global Microbiome Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Microbiome Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (FMT v/s Microbiome Drugs)
  • 5.2.2. By Application (C. Difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Microbiome Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Microbiome Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Microbiome Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Microbiome Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Microbiome Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Microbiome Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Microbiome Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Microbiome Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Microbiome Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Microbiome Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Microbiome Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Microbiome Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Microbiome Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Microbiome Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Microbiome Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Microbiome Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Microbiome Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Microbiome Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Microbiome Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Microbiome Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Microbiome Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Microbiome Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Microbiome Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Microbiome Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Microbiome Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. 4D Pharma plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Enterome SA
• 15.3. Finch Therapeutics Group, Inc.
• 15.4. Vedanta Bioscience, Inc.
• 15.5. Seres Therapeutics, Inc.
• 15.6. Microbiotica Limited
• 15.7. Destiny Pharma plc
• 15.8. Taisho Pharmaceutical Holdings Co., Ltd.
• 15.9. AOBiome Therapeutics, Inc.
• 15.10. Ferring Pharmaceuticals SA

16. Strategic Recommendations

17. About Us & Disclaimer